This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Hoffmann-La Roche Inc.
Hoffmann-La Roche Inc., commonly known as Roche, is a leading global healthcare company headquartered in the United States. Founded in 1896, Roche has established itself as a pioneer in the pharmaceutical and diagnostics industries, with significant operations across North America, Europe, and Asia. The company is renowned for its innovative contributions to oncology, immunology, and infectious diseases, offering a diverse portfolio of prescription medicines and cutting-edge diagnostic tools. Roche's commitment to research and development has led to numerous breakthroughs, positioning it as a market leader in personalised healthcare. Notable achievements include the development of targeted therapies and advanced diagnostics that enhance patient outcomes. With a strong emphasis on innovation and quality, Hoffmann-La Roche Inc. continues to shape the future of healthcare, making a lasting impact on global health.
DitchCarbon Score
How does Hoffmann-La Roche Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hoffmann-La Roche Inc.'s score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hoffmann-La Roche Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. As part of its climate strategy, Hoffmann-La Roche Inc. inherits emissions data and reduction targets from Roche Holding AG. However, no specific reduction targets or achievements have been documented for Hoffmann-La Roche Inc. at this time. The company is aligned with industry standards and initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Roche Holding AG. While specific emissions figures are not provided, Hoffmann-La Roche Inc. is committed to addressing climate change through its parent company's initiatives. The absence of detailed emissions data highlights the need for ongoing transparency and accountability in corporate climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hoffmann-La Roche Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
